The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The relationship between serum hepcidin levels and clinical outcomes in patients with chemotherapy-associated anemia treated in a controlled trial.
D. P. Steensma
Consultant or Advisory Role - Amgen
B. J. Sasu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
J. A. Sloan
No relevant relationships to disclose
D. Tomita
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
C. L. Loprinzi
No relevant relationships to disclose